Navigation Links
PharmAthene Reports Third Quarter 2009 Financial and Operational Results

ANNAPOLIS, Md., Nov. 12 /PRNewswire-FirstCall/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today reported financial and operational results for the third quarter and nine months ended September 30, 2009.

For the third quarter of 2009, PharmAthene recognized revenues of $6.8 million compared to $10.7 million in the same period of 2008. For the nine months ended September 30, 2009 and 2008, the Company reported revenues of $20.4 million and $27.4 million, respectively. Revenues consisted primarily of contract funding from the U.S. government for the development of SparVax(TM), Valortim® and Protexia®.

Research and development expenses were $7.6 million and $9.4 million for the quarter ended September 30, 2009 and 2008, respectively. For the nine months ended September 30, 2009 and 2008, research and development expenses were $22.8 million and $26.5 million, respectively. Research and development expenses for each period consisted primarily of research and development activities related to SparVax(TM), Valortim® and Protexia® development programs and, to a lesser extent, of activities related to RypVax(TM) and the Company's third generation rPA anthrax vaccine program.

General and administrative expenses were $6.2 million and $4.8 million for the quarter ended September 30, 2009 and 2008, respectively. For the nine months ended September 30, 2009 and 2008, general and administrative expenses were $15.8 million and $14.7 million, respectively. The increases in general and administrative expenses for both periods were primarily due to costs associated with the transitioning of the Company's development and manufacturing activities as well as other general and administrative functions from the UK to the United States, and with preparing and submitting various bids and proposals, along with increased non-cash, stock-based compensation costs for the nine month period.

For the third quarter of 2009, PharmAthene's net loss was $14.0 million, or $0.50 per share, compared to $4.3 million or $0.20 per share, in the same period of 2008. For the nine months ended September 30, 2009, the Company's net loss was $26.6 million, or $0.97 per share, compared to $31.2 million, or $1.41 per share in the same period of 2008.

On July 28, 2009, PharmAthene issued 2-year, 10% unsecured senior convertible notes and common stock purchase warrants ("New Convertible Notes and Warrants") in a private placement in the aggregate principal amount of approximately $19.3 million. This private placement included the issuance of $10.5 million in New Convertible Notes and Warrants to new investors for cash and $8.8 million in New Convertible Notes and Warrants in exchange for 8% senior unsecured convertible notes due August 3, 2009 ("Old Notes") and accrued interest in the same amount. The New Convertible Notes issued in exchange for the Old Notes were accounted for as an early extinguishment of debt, resulting in a non-cash loss on extinguishment of debt of approximately $4.7 million. The proceeds from the sale of the New Convertible Notes and Warrants were used to repay $5.5 million of our Old Notes that were not exchanged for the New Convertible Notes and Warrants and to repay all outstanding amounts and fees under our existing credit facility.

As of September 30, 2009, available cash, cash equivalents and short term investments were $11.6 million. In addition, billed and unbilled accounts and other receivables were $18.7 million at September 30, 2009. The Company estimates that at its currently projected rate of net cash consumption, the existing sources of cash and cash receipts from contract receivables will be sufficient to fund operations through the end of 2010.

"We made excellent progress strengthening our balance sheet and continuing to advance our biodefense portfolio in the third quarter of 2009," commented David P. Wright, President and Chief Executive Officer. "New data from our Valortim® and third generation (3G) recombinant protective antigen (rPA) anthrax vaccine programs were presented at the Bacillus - ACT 2009 annual meeting in September. These new data suggest that Valortim® may be capable of killing B. anthracis directly, in addition to its potent toxin neutralization activity."

Conference Call and Webcast Information

PharmAthene management will host a conference call to discuss the Company's third quarter and nine month financial and operational results on November 12, 2009, at 11:00 a.m., E.T. The dial-in number for U.S. callers is 866-700-7173 and for international callers is 617-213-8838. The participant passcode is 45158592.

A replay of the conference call will be available beginning at approximately 2:00 p.m. Eastern Time on November 12, 2009 until approximately 11:59 p.m. Eastern Time December 12, 2009. The dial-in number from within the United States is 888-286-8010. For international callers, the dial-in number is 617-801-6888. The participant passcode is 97434742.

The webcast of the conference call will be available until December 12, 2009 and can be accessed from the company's website at A link to the webcast may be found on the Investor Relations section of the website.

About PharmAthene, Inc.

PharmAthene was formed to meet the critical needs of the United States and its allies by developing and commercializing medical countermeasures against biological and chemical weapons. PharmAthene's lead product development programs include:

  • SparVax(TM) - a second generation recombinant protective antigen (rPA) anthrax vaccine
  • Third generation rPA anthrax vaccine
  • Valortim(R) - a fully human monoclonal antibody for the prevention and treatment of anthrax infection
  • Protexia(R) - a novel bioscavenger for the prevention and treatment of morbidity and mortality associated with exposure to chemical nerve agents
  • RypVax(TM) - a recombinant dual antigen vaccine for plague

For more information about PharmAthene, please visit

Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; "will"; "project"; "potential"; or similar statements are forward-looking statements. PharmAthene disclaims any intent or obligation to update these forward-looking statements other than as required by law. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, including without limitation our bid related to SparVax(TM) under the DHHS Request for Proposals for an Anthrax Recombinant Protective Antigen (rPA) Vaccine for the Strategic National Stockpile, the award of government contracts to our competitors, unforeseen safety issues, challenges related to the development, scale-up, technology transfer, and/or process validation of manufacturing processes for our product candidates, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, as well as risks detailed from time to time in PharmAthene's Forms 10-K and 10-Q under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC").

Copies of PharmAthene's public disclosure filings are available from its investor relations department and our website under the investor relations tab at

-Tables Follow-

                             PHARMATHENE, INC.

                                               September 30,   December 31,
                                                       2009           2008
                                                       ----           ----

     Current assets:
       Cash and cash equivalents                 $4,188,272    $19,752,404
       Restricted cash                                    -     12,000,000
       Short-term investments                     7,382,329      3,190,912
       Accounts receivable                        5,055,107      8,890,077
       Other receivables (including
        unbilled receivables)                    13,668,072      1,391,512
       Prepaid expenses and other
        current assets                            1,765,758        917,125
                                                  ---------        -------
     Total current assets                        32,059,538     46,142,030

     Long-term restricted cash                            -      1,250,000
     Property and equipment, net                  6,207,971      5,313,219
     Patents, net                                   930,350        925,489
     Other long-term assets and deferred costs      423,530        257,623
     Goodwill                                     2,348,453      2,502,909
                                                 ----------     ----------
     Total assets                               $41,969,842    $56,391,270
                                                ===========    ===========


     Current liabilities:
       Accounts payable                          $1,030,171     $3,870,871
       Accrued expenses and other
        current liabilities                      15,252,530     14,624,757
       Convertible notes                                  -     13,377,505
       Current portion of derivative instruments     47,431              -
       Current portion of long-term debt                  -      4,000,000
                                                 ----------     ----------
                                                 16,330,132     35,873,133

     Other long-term liabilities                    446,390        626,581
     Derivative instruments                       2,126,868              -
     Convertible notes and other
     long-term debt                              16,579,864        928,117
                                                 ----------        -------
     Total liabilities                           35,483,254     37,427,831
                                                 ----------     ----------

     Stockholders' equity:
       Common stock, $0.0001 par value;
        100,000,000 shares authorized;
        28,091,635 and 25,890,143 shares
        issued and outstanding, respectively          2,809          2,589
       Additional paid-in-capital               156,242,571    142,392,163
       Accumulated other
        comprehensive income                        879,759        386,351
       Accumulated deficit                     (150,638,551)  (123,817,664)
                                               ------------   ------------
     Total stockholders' equity                   6,486,588     18,963,439
                                                  ---------     ----------
     Total liabilities and
      stockholders' equity                      $41,969,842    $56,391,270
                                                ===========    ===========
                             PHARMATHENE, INC.

                            Three months ended            Nine months ended
                               September 30,                 September 30,
                           2009             2008         2009         2008
                           ----             ----         ----         ----

    Contract revenue     $6,830,399    $10,643,705   $20,423,513  $27,377,207
    Other revenue                 -         32,461             -       53,612
                                ---         ------           ---       ------
                          6,830,399     10,676,166    20,423,513   27,430,819
    Operating expenses:
     Research and
      development         7,609,794      9,414,093    22,769,749   26,475,436
     General and
      administrative      6,224,868      4,803,190    15,787,115   14,655,971
     Acquired in-process
      research and
      development                 -        225,000             -   16,131,002
     Depreciation and
      amortization          247,747        205,409       639,924      641,425
     Other expenses         274,005              -     1,158,566            -
                         ----------     ----------    ----------   ----------
     Total operating
      expenses           14,356,414     14,647,692    40,355,354   57,903,834
                         ----------     ----------    ----------   ----------

    Loss from
     operations          (7,526,015)    (3,971,526)  (19,931,841) (30,473,015)
    Other income(expenses)
     Interest income         61,743        250,014       258,841    1,083,949
     Interest expense      (748,892)      (628,470)   (1,949,402)  (1,947,245)
     Loss on early
      of debt            (4,690,049)             -    (4,690,049)           -
     Change in fair
      value of derivative
      instruments        (1,059,509)         7,604      (295,218)     123,148
                         ----------          -----      --------      -------
     Total other income
      (expenses)         (6,436,707)      (370,852)   (6,675,828)    (740,148)
                         ----------        --------    ----------     --------

    Net loss            (13,962,722)    (4,342,378)  (26,607,669) (31,213,163)
    Basic and diluted
     net loss per share      $(0.50)        $(0.20)       $(0.97)      $(1.41)
    Weighted average
     shares used in
     calculation of
     basic and diluted
     net loss per share  28,077,348     22,095,545    27,388,761   22,089,949

SOURCE PharmAthene, Inc.

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
2. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
3. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
4. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
5. PharmAthene to Present at the BIO CEO & Investor Conference 2008
6. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
7. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
8. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
9. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
10. PharmAthene to Delay Release of Full Year 2007 Financial Results
11. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008
Post Your Comments:
(Date:11/25/2015)... Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: PIP) ... a stockholder rights plan (Rights Plan) in an effort ... carryforwards (NOLs) under Section 382 of the Internal Revenue ... PharmAthene,s use of its NOLs could be substantially ... defined in Section 382 of the Code. In general, ...
(Date:11/25/2015)... and HOLLISTON, Mass. , Nov. ... (Nasdaq: HART ), a biotechnology company developing bioengineered ... Jim McGorry will present at the LD ... 2015 at 2:30 p.m. PT. The presentation will be ... 30 days. Management will also be available at the ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... and the Organization of Black Aerospace Professionals (OPBAP) has been formalized with the ... other AMA team leaders met with OPBAP leaders Capt. Karl Minter and Capt. ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and Zachary ... in their initial angel funding process. Now, they are paying it forward to ... early stage investments in the microbiome space. In this, they join other ...
Breaking Biology Technology:
(Date:10/29/2015)... 29, 2015   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that it ... (MHTA) as one of only three finalists for a ... Small and Growing" category. The Tekne Awards honor ... superior technology innovation and leadership. iMedNet™ ...
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, ... for U.S. distribution of its DNA library preparation ... and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq ... the preparation of NGS libraries for liquid biopsies--the ... diagnostic and prognostic applications in cancer and other ...
(Date:10/29/2015)... , Oct. 29, 2015 Today, ... announced a partnership with 2XU, a global leader ... deliver a smart hat with advanced bio-sensing technology. ... other athletes to monitor key biometrics to improve ... strategic partnership, the two companies will bring together the ...
Breaking Biology News(10 mins):